Mesenchymal stem cells in osteoarticular diseases

Regenerative Medicine

Volumn 6, Issue 6 SUPPL., 2011, Pages 44-51

  Jorgensen, Christian ^a   Noël, Danièle ^b  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH REGULATORY PROTEIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 3; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROSTAGLANDIN E2; REGULATOR PROTEIN; STROMAL CELL DERIVED FACTOR 1; TISSUE SCAFFOLD; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOSE TISSUE; ADIPOSE TISSUE DERIVED STEM CELL; ADULT STEM CELL; APOPTOSIS; ARTICLE; AUTOLOGOUS CHONDROCYTE IMPLANTATION; B LYMPHOCYTE; BREAST CANCER; CANCER CELL; CARTILAGE CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELL TRANSPLANTATION; CHONDROGENESIS; CYTOKINE RELEASE; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPOTENT STEM CELL; NONHUMAN; OSTEOARTHRITIS; OSTEOARTHROPATHY; PARACRINE SIGNALING; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE; TISSUE ENGINEERING;

ADULT STEM CELLS; ANIMALS; BONE DISEASES; CELL DIFFERENTIATION; HUMANS; JOINT DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MODELS, BIOLOGICAL;

EID: 80054098557     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.11.80     Document Type: Article

References (66)

1. Vinatier C, Mrugala D, Jorgensen C et al. Cartilage engineering: a crucial combination of cells, biomaterials and biofactors. Trends Biotechnol. 27(5), 307-314 (2009).
2. Chen Y, Shao JZ, Xiang LX et al. Mesenchymal stem cells: a promising candidate in regenerative medicine. Int. J. Biochem. Cell Biol. 40(5), 815-820 (2008).
3. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4), 315-317 (2006). □□ Definition of parameters that are required to characterize a mesenchymal stromal cell.
4. Ghannam S, Bouffi C, Djouad F et al. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res. Ther. 1(1), 2 (2010).
5. Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418(6893), 41-49 (2002).
6. Tropel P, Platet N, Platel JC et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 24(12), 2868-2876 (2006).
7. Delorme B, Ringe J, Pontikoglou C et al. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity Stem Cells 27(5), 1142-1151 (2009).
8. Chen FH, Tuan RS. Mesenchymal stem cells in arthritic diseases. Arthritis Res. Ther. 10(5), 223 (2008).
9. Barry F, Boynton RE, Liu B et al. Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp. Cell Res. 268(2), 189-200 (2001).
10. Kafienah W, Mistry S, Dickinson SC et al. Three-dimensional cartilage tissue engineering using adult stem cells from osteoarthritis patients. Arthritis Rheum. 56(1), 177-187 (2007).
11. Mrugala D, Dossat N, Ringe J et al. Gene expression profile of multipotent mesenchymal stromal cells: identification of pathways common to TGFb3/BMP2-induced chondrogenesis. Cloning Stem Cells 11(1), 61-76 (2009).
12. Djouad F, Bony C, Canovas F et al. Transcriptomic analysis identifies Foxo3A as a novel transcription factor regulating mesenchymal stem cell chrondrogenic differentiation. Cloning Stem Cells 11(3), 407-416 (2009). □ One of the first reports identifying the foxo signaling pathway in the process of diferentiation of mesenchymal stem cells (MSCs).
13. Djouad F, Delorme B, Maurice M et al. Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes. Arthritis Res. Ther. 9(2), R33 (2007).
14. Ringden O, Le Blanc K. Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. APMIS 113(11-12), 813-830 (2005).
15. Mias C, Lairez O, Trouche E et al. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 27(11), 2734-2743 (2009).
16. Li L, Zhang Y, Li Y et al. Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenolinduced global heart failure. Transpl. Int. 21(12), 1181-1189 (2008).
17. Huang HI, Chen SK, Ling QD et al. Multilineage differentiation potential of fibroblast-like stromal cells derived from human skin. Tissue Eng Part A 16(5), 1491-1501 (2009).
18. Mirotsou M, Zhang Z, Deb A et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cellreleased paracrine factor mediating myocardial survival and repair. Proc. Natl Acad. Sci. USA 104(5), 1643-1648 (2007).
19. Wang F, Yasuhara T, Shingo T et al. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1a. BMC Neurosci. 11, 52 (2010).
20. Kinnaird T, Stabile E, Burnett MS et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 94(5), 678-685 (2004).
21. Nguyen BK, Maltais S, Perrault LP et al. Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. J. Cardiovasc. Transl. Res. 3(5), 547-558 (2010).
22. Rehman J, Traktuev D, Li J et al. Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 109(10), 1292-1298 (2004).
23. Honczarenko M, Le Y, Swierkowski M et al. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 24(4), 1030-1041 (2006).
24. Dar A, Goichberg P, Shinder V et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. Nat. Immunol. 6(10), 1038-1046 (2005).
25. Wynn RF, Hart CA, Corradi-Perini C et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 104(9), 2643-2645 (2004).
26. Kitaori T, Ito H, Schwarz EM et al. Stromal cell-derived factor 1/CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model. Arthritis Rheum. 60(3), 813-823 (2009).
27. Ma J, Ge J, Zhang S et al. Time course of myocardial stromal cell-derived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res. Cardiol. 100(3), 217-223 (2005).
28. Schenk S, Mal N, Finan A et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 25(1), 245-251 (2007).
29. Dwyer RM, Potter-Beirne SM, Harrington KA et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin. Cancer Res. 13(17), 5020-5027 (2007).
30. Lin SY, Yang J, Everett AD et al. The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells. Exp. Cell Res. 314(17), 3107-3117 (2008).
31. Mishra PJ, Mishra PJ, Humeniuk R et al Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 68(11), 4331-4339 (2008).
32. Dittmer A, Hohlfeld K, Lutzkendorf J et al. Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10. Cell. Mol. Life Sci. 66(18), 3053-3065 (2009).
33. Karnoub AE, Dash AB, Vo AP et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162), 557-563 (2007).
34. Dittmer J. Mesenchymal stem cells: "repair cells" that serve wounds and cancer? Scientific World Journal 10, 1234-1238 (2010).
35. Klopp AH, Gupta A, Spaeth E et al. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29(1), 11-19 (2011).
36. Studeny M, Marini FC, Champlin RE et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-p delivery into tumors. Cancer Res. 62(13), 3603-3608 (2002).
37. Studeny M, Marini FC, Dembinski JL et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeteddelivery vehicles for anticancer agents. J. Natl Cancer Inst. 96(21), 1593-1603 (2004). □ An important reference on the use of MSCs in the delivery of anticancer agents.
38. Nakamizo A, Marini F, Amano T et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65(8), 3307-3318 (2005).
39. Nakamura K, Ito Y, Kawano Y et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11(14), 1155-1164 (2004).
40. Kidd S, Caldwell L, Dietrich M et al. Mesenchymal stromal cells alone or expressing interferon-β suppress pancreatic tumors in vivo, an effect countered by antiinflammatory treatment. Cytotherapy 12(5), 615-625 (2010).
41. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2(2), 141-150 (2008).
42. Bouffi C, Bony C, Courties G et al. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS ONE 5(12), e14247 (2010).
43. Yanez R, Oviedo A, Aldea M et al. Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells. Exp. Cell Res. 316(19), 3109-3123 (2010).
44. Mougiakakos D, Jitschin R, Johansson CC et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117(18), 4826-4835 (2011).
45. Schena F, Gambini C, Gregorio A et al. Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum. 62(9), 2776-2786
46. Djouad F, Charbonnier LM, Bouffi C et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25(8), 2025-2032 (2007). □ One of the first references reporting the modulatory role of MSCs in the generation and function of dendritic cells.
47. +-derived and monocyte-derived dendritic cells. J. Immunol. 177(4), 2080-2087 (2006).
48. Ghannam S, Pene J, Torcy-Moquet G et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 185(1), 302-312 (2010).
49. Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos. Int. 22(2), 435-446 (2011).
50. Huang H, Kim HJ, Chang EJ et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ. 16(10), 1332-1343 (2009).
51. + T lymphocytes preferentially reside and rest in the bone marrow. Immunity 30(5), 721-730 (2009).
52. Waterman RS, Tomchuck SL, Henkle SL et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a proinfammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE 5(4), e10088 (2010).
53. Murphy JM, Fink DJ, Hunziker EB et al. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 48(12), 3464-3474 (2003). □□ An important study describing the regenerative function of MSCs in a large preclinical model of osteoarthritis.
54. Davatchi F, Abdollahi BS, Mohyeddin M et al. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int. J. Rheum. Dis. 14(2), 211-215 (2011).
55. Augello A, Tasso R, Negrini SM et al. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 56(4), 1175-1186 (2007).
56. Gonzalez-Rey E, Gonzalez MA, Varela N et al. Human adipose-derived mesenchymal stem cells reduce inflammatory and T-cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann. Rheum. Dis. 69(1), 241-248 (2010). □ A report on the therapeutic efect of MSCs in rheumatoid arthritis highlighting the role of regulatory T cells.
57. Djouad F, Fritz V, Apparailly F et al. Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor α in collageninduced arthritis. Arthritis Rheum. 52(5), 1595-1603 (2005).
58. Schurgers E, Kelchtermans H, Mitera T et al. Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res. Ther. 12(1), R31 (2010).
59. Brittberg M. Cell carriers as the next generation of cell therapy for cartilage repair: a review of the matrix-induced autologous chondrocyte implantation procedure. Am. J. Sports Med. 38(6), 1259-1271 (2010).
60. Vavken P, Samartzis D. Effectiveness of autologous chondrocyte implantation in cartilage repair of the knee: a systematic review of controlled trials. Osteoarthritis Cartilage 18(6), 857-863 (2010).
61. Kuroda R, Ishida K, Matsumoto T et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. Osteoarthritis Cartilage 15(2), 226-231 (2007).
62. Wakitani S, Imoto K, Yamamoto T et al. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage 10(3), 199-206 (2002).
63. Wakitani S, Mitsuoka T, Nakamura N et al. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. Cell Transplant. 13(5), 595-600 (2004).
64. Wakitani S, Nawata M, Tensho K et al. Repair of articular cartilage defects in the patello-femoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. J. Tissue Eng. Regen. Med. 1(1), 74-79 (2007).
65. Haleem AM, Singergy AA, Sabry D et al. The clinical use of human cultureexpanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results. Cartilage 1(4), 253-261 (2010).
66. Nejadnik H, Hui JH, Feng Choong EP et al. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. Am. J. Sports Med. 38(6), 1110-1116 (2010).